文献类型：期刊文献

英文题名：Comprehensive analysis of the effects of the cuprotosis-associated gene SLC31A1 on patient prognosis and tumor microenvironment in human cancer

作者：Zhang, Guiqian[1,2,3,4];Wang, Ning[1];Ma, Shixun[2,3,4];Tao, Pengxian[2,3,4];Cai, Hui[2,3,4]

第一作者：Zhang, Guiqian

通信作者：Tao, PX[1];Cai, H[1];Tao, PX[2];Cai, H[2];Tao, PX[3];Cai, H[3]

机构：[1]Gansu Univ Chinese Med, Gansu Prov Hosp, Clin Med Coll 1, Lanzhou, Peoples R China;[2]Gansu Prov Hosp, Clin Med Ctr, Gen Surg, 204 Donggang West Rd, Lanzhou 730000, Peoples R China;[3]Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou, Peoples R China;[4]Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumors, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Prov Hosp, Clin Med Ctr, Gen Surg, 204 Donggang West Rd, Lanzhou 730000, Peoples R China;[2]corresponding author), Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gansu, Lanzhou, Peoples R China;[3]corresponding author), Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumors, Lanzhou, Peoples R China.

年份：2024

卷号：13

期号：2

起止页码：714

外文期刊名：TRANSLATIONAL CANCER RESEARCH

收录：;Scopus(收录号：2-s2.0-85187196198);WOS:【SCI-EXPANDED(收录号:WOS:001225032900009)】；

基金：This work was supported by grants from the National Natural Science Foundation of China (82360498), Gansu Joint Scientific Research Fund Major Project under Grant (23JRRA1537), Gansu Provincial People's Hospital Key Research Fund (20GSSY1-11), 2021 Central-Guided Local Science and Technology Development Fund (ZYYDDFFZZJ-1), Key Talent Project of Gansu Province of the Organization Department of Gansu Provincial Party Committee (2020RCXM076), Gansu Provincial Youth Science and Technology Fund Program (21JR7RA642), Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences (21GSSYC-2), Gansu Key Laboratory of Molecular Diagnosis and Precision Treatment of Surgical Tumors (18JR2RA033), Gansu Provincial People's Hospital Excellent Master/PhD Student Incubation Program Project Fund (22GSSYD-19), Natural Science Foundation of Gansu Province (21JR11RA186), National Health Care Commission Key Laboratory of Gastrointestinal Tumor Diagnosis and Treatment Open Fund (NHCDP2022022), and Key Project of Science and Technology Innovation Platform Fund of Gansu Provincial People's Hospital (21gssya-4).

语种：英文

外文关键词：Cuprotosis; solute carrier family 31 (copper transporter); human cancer; prognosis; tumor microenvironment (TME)

摘要：Background: Solute carrier family 31 (copper transporter), member 1 ( SLC31A1 ) is a key factor in maintaining intracellular copper concentration and an important factor affecting cancer energy metabolism. Therefore, exploring the potential biological function and value of SLC31A1 could provide a new direction for the targeted therapy of tumors. Methods: This study assessed gene expression levels, survival, clinicopathology, gene mutations, methylation levels, the tumor mutational burden (TMB), microsatellite instability (MSI), and the immune cell infiltration of SLC31A1 in pan -cancer using the Tumor Immune Estimation Resource 2.0 (TIMER2.0), Gene Expression Profiling Interactive Analysis (GEPIA), University of Alabama at Birmingham CANcer (UALCAN) data analysis portal, and cBioPortal databases. To further understand the potential biological mechanisms of SLC31A1 in different cancers, single -cell level sequencing and a Gene Ontology/Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) enrichment analysis of SLC31A1 were also performed. Finally, real-time quantitative polymerase chain reaction (RT-qPCR) and western blotting (WB) were used to validate the expression of SLC31A1 in cancers, such as gastric cancer. Results: SLC31A1 was expressed in most cancer tissues. In kidney renal clear cell carcinoma (KIRC), the high expression of SLC31A1 was associated with good overall survival (OS), while in adrenocortical carcinoma (ACC), breast invasive carcinoma (BRCA), lower grade glioma (LGG), mesothelioma (MESO), and skin cutaneous melanoma (SKCM), the low expression of SLC31A1 was associated with good OS. The highest frequency of SLC31A1 amplification was observed in ACC. In addition, missense mutations accounted for a major portion of the mutation types. The truncation mutation S105Y may be a putative cancer driver. SLC31A1 affected methylation levels in cancer and was associated with the TMB, MSI, and the level of infiltration of various immune cells. Additionally, the single -cell sequencing results showed that SLC31A1 was associated with multiple biological functions in cancer. Finally, the SLC31A1 enrichment analysis revealed that the SLC31A1 -related genes were mainly enriched in the mitochondrial matrix and envelope vesicles. The RT-qPCR and WB results were consistent with the predicted results. Conclusions: SLC31A1 may be a potential target related to cancer energy metabolism and may have prognostic value.